Arrowstreet Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-721,200
Closed -$88.5M 1951
2025
Q4
$88.5M Buy
721,200
+62,544
+9% +$7.6M 0.05% 316
2025
Q3
$73.1M Buy
658,656
+232,072
+54% +$26.4M 0.05% 364
2025
Q2
$47.3M Buy
426,584
+372,596
+690% +$39.7M 0.03% 436
2025
Q1
$6.05M Sell
53,988
-85,618
-61% -$8.83M ﹤0.01% 968
2024
Q4
$12.9M Sell
139,606
-2,857,063
-95% -$257M 0.01% 745
2024
Q3
$251M Sell
2,996,669
-1,588,535
-35% -$121M 0.21% 95
2024
Q2
$315M Sell
4,585,204
-461,229
-9% -$30.8M 0.28% 85
2024
Q1
$370M Sell
5,046,433
-3,331,941
-40% -$256M 0.34% 68
2023
Q4
$679M Sell
8,378,374
-1,839,296
-18% -$143M 0.71% 27
2023
Q3
$766M Buy
10,217,670
+1,330,560
+15% +$102M 0.93% 23
2023
Q2
$685M Buy
8,887,110
+695,909
+8% +$55.5M 0.83% 21
2023
Q1
$680M Sell
8,191,201
-24,833
-0.3% -$2.06M 0.88% 20
2022
Q4
$705M Sell
8,216,034
-3,820,541
-32% -$303M 0.99% 15
2022
Q3
$743M Sell
12,036,575
-3,631,610
-23% -$229M 1.1% 14
2022
Q2
$968M Sell
15,668,185
-2,334,029
-13% -$145M 1.37% 10
2022
Q1
$1.07B Buy
18,002,214
+13,764,169
+325% +$880M 1.34% 7
2021
Q4
$308M Buy
4,238,045
+4,201,326
+11,442% +$289M 0.38% 61
2021
Q3
$2.56M Sell
36,719
-580,425
-94% -$40.8M ﹤0.01% 1076
2021
Q2
$42.5M Buy
+617,144
New +$41.2M 0.05% 366
2021
Q1
Sell
-3,082,197
Closed -$180M 2341
2020
Q4
$180M Buy
3,082,197
+949,275
+45% +$57.3M 0.25% 70
2020
Q3
$135M Buy
2,132,922
+152,480
+8% +$10.6M 0.21% 85
2020
Q2
$152M Buy
1,980,442
+881,065
+80% +$67.5M 0.28% 64
2020
Q1
$82.2M Sell
1,099,377
-690,815
-39% -$47.7M 0.23% 83
2019
Q4
$116M Buy
1,790,192
+14,088
+0.8% +$917K 0.27% 74
2019
Q3
$113M Sell
1,776,104
-1,818,029
-51% -$119M 0.26% 95
2019
Q2
$243M Buy
3,594,133
+341,000
+10% +$22.4M 0.54% 45
2019
Q1
$211M Buy
3,253,133
+2,073,539
+176% +$138M 0.5% 40
2018
Q4
$73.8M Sell
1,179,594
-153,107
-11% -$10.7M 0.19% 123
2018
Q3
$103M Sell
1,332,701
-1,174,582
-47% -$88.7M 0.23% 103
2018
Q2
$178M Sell
2,507,283
-668,464
-21% -$47.2M 0.43% 63
2018
Q1
$239M Buy
3,175,747
+105,420
+3% +$8.38M 0.55% 42
2017
Q4
$220M Buy
3,070,327
+3,046,047
+12,545% +$231M 0.53% 44
2017
Q3
$1.97M Buy
+24,280
New +$1.86M 0.01% 707
2017
Q2
Sell
-864,955
Closed -$58.7M 1163
2017
Q1
$58.7M Buy
+864,955
New +$60.8M 0.22% 120
2016
Q4
Sell
-14,400
Closed -$1.14M 1984
2016
Q3
$1.14M Buy
+14,400
New +$1.17M ﹤0.01% 1044
2016
Q2
Sell
-413,300
Closed -$38M 1398
2016
Q1
$38M Buy
413,300
+11,500
+3% +$1.04M 0.16% 145
2015
Q4
$40.7M Buy
401,800
+306,000
+319% +$31.8M 0.19% 118
2015
Q3
$9.41M Buy
+95,800
New +$10.6M 0.04% 357
2015
Q1
Sell
-2,247,420
Closed -$212M 1080
2014
Q4
$212M Buy
2,247,420
+107,192
+5% +$11.1M 1.21% 13
2014
Q3
$228M Buy
2,140,228
+1,807,032
+542% +$177M 1.22% 13
2014
Q2
$27.6M Sell
333,196
-3,182,295
-91% -$248M 0.14% 154
2014
Q1
$249M Buy
3,515,491
+383,862
+12% +$30.1M 1.51% 6
2013
Q4
$235M Buy
3,131,629
+551,307
+21% +$38.4M 1.27% 7
2013
Q3
$162M Buy
2,580,322
+1,072,859
+71% +$64.1M 1.03% 20
2013
Q2
$77.2M Buy
+1,507,463
New +$78.6M 0.58% 49

Other funds holding GILD

Arrowstreet Capital's GILD Position: Q1 2026 in Review

Arrowstreet Capital sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 721,200 shares — an estimated $88.5M sold.

Arrowstreet Capital first reported a position in GILD in Q2 2013 and held it in 45 quarters. The position peaked at $1.07B in Q1 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Arrowstreet Capital reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 721,200 Gilead Sciences shares in Q1 2026, an estimated $88.5M.
  • Arrowstreet Capital first reported a position in Gilead Sciences in Q2 2013 and held it in 45 quarters.
  • Arrowstreet Capital's Gilead Sciences position peaked at $1.07B in Q1 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.